revumenib
syndax pharma
['revumenib', 'leusm', 'augment,data', 'augment-101', 'leukemia']
#ash22 #leusm issa: revumenib significantly causes qtc prolongation (53%, 13% gr3+). cr/crh 30%. orr 52% at rp2d with 27% cr/crh, 15% mlfs. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)